TCGA-E2-A153-01A-12R-A12D-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 24
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.700
- ANGIOGENESIS+0.580
- COAGULATION+0.510
- ESTROGEN_RESPONSE_EARLY+0.490
- HYPOXIA+0.490
- MYOGENESIS+0.430
- TNFA_SIGNALING_VIA_NFKB+0.430
- HEDGEHOG_SIGNALING+0.420
- UV_RESPONSE_DN+0.420
- TGF_BETA_SIGNALING+0.400
Top 10 suppressed
- E2F_TARGETS-0.710
- G2M_CHECKPOINT-0.620
- MYC_TARGETS_V1-0.570
- MYC_TARGETS_V2-0.540
- OXIDATIVE_PHOSPHORYLATION-0.490
- DNA_REPAIR-0.380
- SPERMATOGENESIS-0.270
- MITOTIC_SPINDLE-0.250
- UNFOLDED_PROTEIN_RESPONSE-0.250
- FATTY_ACID_METABOLISM-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4c7083b3-eccc-4d80-a31d-6fd3cd0222b4 | — | — | 0.935 |
| 2 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.930 |
| 3 | TCGA-OL-A6VQ-01A-12R-A41B-07 | — | A | 0.928 |
| 4 | TCGA-56-A4ZJ-01A-11R-A262-07 | — | cohortSQ1 | 0.926 |
| 5 | 6b548699-9440-4acc-86b6-faeb367454a2 | — | — | 0.923 |
| 6 | TCGA-AC-A23G-01A-11R-A213-07 | — | A | 0.921 |
| 7 | SRR8518199 | — | A | 0.914 |
| 8 | TCGA-BH-A0AZ-01A-21R-A12P-07 | — | A | 0.909 |
| 9 | TCGA-K4-A4AB-01B-12R-A28M-07 | — | — | 0.906 |
| 10 | TCGA-BH-A0DV-01A-21R-A12P-07 | — | A | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.700 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.580 | Remibrutinib | — uncovered |
| COAGULATION | 0.510 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.490 | Inavolisib | — uncovered |
| HYPOXIA | 0.490 | Idelalisib | — uncovered |
| MYOGENESIS | 0.430 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.390 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.370 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.340 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.330 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |